2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 806

Posterior Insula Combined Glutamate and Glutamine Is Associated with Pain in Fibromyalgia: A Replication Study
Abstract Number: 2511

Potential Barriers That Limit Access to Rheumatologists Among Patients with Early Rheumatoid Arthritis in a Universal Access Health Care System
Abstract Number: 762

Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis
Abstract Number: 808

Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study
Abstract Number: 113

Power Doppler Signal Is Frequently Positive Among Patients with Rheumatoid Arthritis in Clinical Remission and Normal Serum Matrix Metalloproteinase-3 (MMP-3) Levels
Abstract Number: 2587

Practice Makes Perfect: Assessment of Proficiency of Rheumatology Fellows in Specific Joint Procedural Skills
Abstract Number: 1540

Practice Patterns in the Treatment of ANCA-Associated Vasculitis: Exploring Differences Among Subspecialties At a Single Academic Medical Center
Abstract Number: 66

Pre-Rheumatoid Arthritis (pre-RA) Subjects Had a Minority Excess with Clearly Low Serum Cortisol Levels and Females Had Lower Mean Androstenedione Levels Than Control (CN) Cohorts in Analysis of a Large Panel of Serum Steroids and Pituitary Hormones
Abstract Number: 336

Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody^®For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Abstract Number: 2244

Predicting Sjögren’s Syndrome At Diagnosis of Systemic Lupus Erythematosus
Abstract Number: 87

Prediction of Mortality in Rheumatoid Arthritis Using a Serum Cytokine Profile
Abstract Number: 1119

Prediction of MRI-Detected Cartilage Loss Over 30 Months Using Simplified Radiographic and Clinical Stratification: The MOST Study
Abstract Number: 1706

Predictive Atherosclerotic Risk Factors At Inception in a Multicentre, Multinational Cohort
Abstract Number: 2593

Predictive Markers of Therapeutical Outcome and Their Role in the Ethiopathology of Juvenile Idiopathic Arthritis
Abstract Number: 1309

Predictive Risk Factors of Serious Infections in RA Patients Treated with Abatacept in Real Life: Results in the Orencia and Rheumatoid Arthritis (ORA) Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].